Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine

Kamada,Minori; Akiyoshi,Kohei; Akiyama,Nobutake; Funamizu,Naotake; Watanabe,Michiko; Fujioka,Kouki; Ikeda,Kei-Ichi; Manome,Yoshinobu

doi:10.3892/or.2014.3227

Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine

Authors:
- Minori Kamada
- Kohei Akiyoshi
- Nobutake Akiyama
- Naotake Funamizu
- Michiko Watanabe
- Kouki Fujioka
- Kei-Ichi Ikeda
- Yoshinobu Manome
View Affiliations

Affiliations: Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan, Department of Molecular Cell Biology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan, Department of Molecular Immunology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan, Department of Surgery, Jikei University School of Medicine, Tokyo, Japan, Institute of DNA Sciences, Yokohama, Japan
Published online on: May 30, 2014 https://doi.org/10.3892/or.2014.3227
Pages: 829-834

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma is a disease with a poor prognosis. A human cholangiocarcinoma cell line, TK, was previously established to enable further understanding of the disease. We conducted this investigation to determine whether or not the TK line is useful for pharmacokinetic study of the chemotherapeutic agent gemcitabine (GEM). Along with the BXPC3 human pancreatic adenocarcinoma cell line, the sensitivity to and effects on the TK cell line of GEM were compared. The influence of deoxycytidine kinase (dCK) transduction was also comparatively investigated. The effects of GEM in terms of drug sensitivity of the TK cell line, cell cycle and levels of transcripts of key enzymes were comparable to the BXPC3 cell line. Responses to the drug were similar in both cell lines. In contrast to pancreatic carcinoma, cell lines for research on cholangiocarcinoma have been limited. This study suggests the application of the TK cell line to the pharmacokinetic study of the chemosensitization of therapeutic drugs, such as GEM.

View Figures

View References

1	Kumagai S, Kurumatani N, Arimoto A and Ichihara G: Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med. 70:508–510. 2013. View Article : Google Scholar : PubMed/NCBI
2	Faris JE and Zhu AX: Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci. 19:326–336. 2012. View Article : Google Scholar : PubMed/NCBI
3	Sato J, Kimura T, Saito T, et al: Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 18:700–711. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M and Miyazaki K: Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep. 20:279–286. 2008.PubMed/NCBI
5	Borbath I, Verbrugghe L, Lai R, Gigot JF, Humblet Y, Piessevaux H and Sempoux C: Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur J Cancer. 48:990–996. 2012. View Article : Google Scholar
6	Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
7	Pignochino Y, Sarotto I, Peraldo-Neia C, et al: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 10:6312010. View Article : Google Scholar : PubMed/NCBI
8	Saito S, Ghosh M, Morita K, Hirano T, Miwa M and Todoroki T: The genetic differences between gallbladder and bile duct cancer cell lines. Oncol Rep. 16:949–956. 2006.PubMed/NCBI
9	Selaru FM, Olaru AV, Kan T, et al: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI
10	Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
11	Watanabe M, Chigusa M, Takahashi H, Nakamura J, Tanaka H and Ohno T: High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo. In Vitro Cell Dev Biol Anim. 36:104–109. 2000. View Article : Google Scholar : PubMed/NCBI
12	Akiyoshi K, Kamada M, Akiyama N, et al: Morphological study of cholangiocarcinoma cell line, TK with three-dimensional cell culture. Mol Med Rep. 9:1359–1364. 2014.PubMed/NCBI
13	Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW and Fine HA: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med. 2:567–573. 1996. View Article : Google Scholar : PubMed/NCBI
14	Kamada M, Ikeda K, Fujioka K, et al: Expression of mRNAs of urocortin and corticotropin-releasing factor receptors in malignant glioma cell lines. Anticancer Res. 32:5299–5307. 2012.PubMed/NCBI
15	Funamizu N, Lacy CR, Fujita K, Furukawa K, Misawa T, Yanaga K and Manome Y: Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 7:e374242012. View Article : Google Scholar : PubMed/NCBI
16	Suzuki R, Kojima H, Moriyama H and Manome Y: Utilization of caspase-14 promoter for selective transgene expression in squamous layers of cholesteatoma in the middle ear. J Intl Adv Otol. 8:21–29. 2012.
17	Manome Y, Wen PY, Chen L, et al: Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther. 3:513–520. 1996.
18	Funamizu N, Okamoto A, Kamata Y, et al: Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase? Oncol Rep. 23:471–475. 2010.PubMed/NCBI
19	de Marsh RW, Alonzo M, Bajaj S, et al: Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology. J Surg Oncol. 106:332–338. 2012.PubMed/NCBI
20	Yonemori K, Ueno H, Okusaka T, et al: Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res. 11:2620–2624. 2005. View Article : Google Scholar : PubMed/NCBI
21	Nakahira S, Nakamori S, Tsujie M, et al: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 120:1355–1363. 2007. View Article : Google Scholar : PubMed/NCBI
22	Ohhashi S, Ohuchida K, Mizumoto K, et al: Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res. 28:2205–2212. 2008.PubMed/NCBI
23	Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N and Sueda T: Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg. 256:288–296. 2012. View Article : Google Scholar
25	Murata A, Amano R, Yamada N, Kimura K, Yashiro M, Nakata B and Hirakawa K: Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. World J Surg Oncol. 11:1172013. View Article : Google Scholar
26	Sebastiani V, Ricci F, Rubio-Viqueira B, et al: Immuno-histochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 12:2492–2497. 2006. View Article : Google Scholar
27	Hapke D, Stegmann A and Mitchell B: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56:2343–2347. 1996.PubMed/NCBI
28	Mori R, Ishikawa T, Ichikawa Y, et al: Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep. 17:1201–1205. 2007.